| Next 10 |
BLUE News and Press, bluebird bio Inc.
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...
-
Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...
-
Switzerland's Roche (OTCQX:RHHBY) (OTCQX:RHHBF) and bluebird bio (BLUE) are resolving a trademark infringement litigation related to the Cambridge, Mass.-based gene therapy company's sickle cell disease (SCD) awareness campaign, "Be the Spark," Fierce Pharma reported. Roche's gene t...
-
Bluebird bio (NASDAQ:BLUE) stock rose ~6% on May 17 amid Morgan Stanley lowering its price target on the gene therapy developer's shares to $3 from $5. Morgan Stanley analyst maintained an Underweight rating on the shares. Following the company's Q1 earnings about a week ago Barclay...
-
bluebird bio (BLUE +10.1%) Q1 shows a revenue beat of $1.78M to $1.95, up +119.1% Y/Y. Research and development expenses from continuing operations were $77.9 million for the three months ended March 31, 2022, compared to $82.8 million for the three months ended March 31, 2021. Restricted cas...
-
bluebird bio press release (NASDAQ:BLUE): Q1 GAAP EPS of -$1.66 misses by $0.30. Revenue of $1.95M (+119.1% Y/Y) beats by $1.78M. Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-end 2022 For further details see: bluebird bio GAAP EPS of -$1...
-
- BLAs for beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-en...
-
Potential to receive FDA approval of beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukoodystrophy in 2022. FDA approvals of beti-cel and eli-cel would give bluebird bio the ability to receive Priority Review Vouchers which it could sell for upwards of over $100 million...
-
A turnaround plays are highly risky yet you found them in the land of multi-baggers. BioLife shares have tumbled substantially due to various issues like supply-chain that cannot keep pace with the company's growth by acquisition strategy. There are also management changes and the...
-
The past few years have been harsh on Bluebird Bio (NASDAQ: BLUE) . The rare-diseases-focused, gene-therapy specialist ran into a series of clinical and regulatory headwinds, which played a major role in its catastrophic performance in the stock market since 2019. Bluebird's shares ...
Stock Information
MENU
BLUE
BLUE Quote
BLUE Short
BLUE News
BLUE Articles
Get BLUE Alerts
News, Short Squeeze, Breakout and More Instantly...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article covers seven cheap biotech stocks for investors with a high risk tolerance. ImmunityBio ( IBRX ): Boasts an extensive pipeline that covers multiple chronic conditions. Selecta Biosciences ( SELB ...
-
Going against prevailing market trends can be tricky, but it can also be a rewarding strategy. Uncovering gems in the stock market that most other investors are ignoring -- or actively avoiding -- can be highly profitable in the long term. Of course, scooping up shares of beaten-down stocks...
-
BLUE - bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
- BLAs for beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by 35 to 40 percent by year-en...